Cisco
CSCO
Alibaba
BABA
Disney
DIS
Apple
AAPL
Qualcomm
QCOM
US Stock MarketDetailed Quotes
TENX Tenax Therapeutics
- 6.1320
- -0.1280-2.04%
Close Mar 26 16:00 ET
- 6.6655
- +0.5335+8.70%
Post 20:01 ET
24.35MMarket Cap-5.33P/E (TTM)
6.7100High6.0400Low23.37KVolume6.7100Open6.2600Pre Close145.61KTurnover0.59%Turnover RatioLossP/E (Static)3.97MShares7.890052wk High0.26P/B24.29MFloat Cap2.770052wk Low--Dividend TTM3.96MShs Float21599978.4000Historical High--Div YieldTTM10.70%Amplitude2.7700Historical Low6.2310Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Tenax Therapeutics Stock Forum
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost
Tenax Therapeutics Announces $25 Million Private Placement
Tenax Secures FDA Green Light for Dual Phase 3 Trials in Untreated Heart Condition
Tenax Therapeutics Announces $25 Million Private Placement
Wednesday, 5th March at 8:47 am
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ: TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Inve...
Tenax Therapeutics : Agreement by FDA to Initiate Second Global Phase 3 Study, Level-2, With First Patient Expected to Be Enrolled This Year
Tenax Secures FDA Green Light for Dual Phase 3 Trials in Untreated Heart Condition
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Wednesday, 5th March at 8:42 am
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025
Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with First Patient Expected to be Enrolled this Year
CHAPEL HILL, N.C., March 0...
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
No comment yet